{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:17:04Z","timestamp":1790007424969,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2006,12,5]],"date-time":"2006-12-05T00:00:00Z","timestamp":1165276800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1245\/s10434-006-9123-8","type":"journal-article","created":{"date-parts":[[2006,12,4]],"date-time":"2006-12-04T21:39:15Z","timestamp":1165268355000},"page":"752-758","source":"Crossref","is-referenced-by-count":16,"title":["COX-2 Expression in Hepatocellular Carcinoma is an Initiation Event; While EGF Receptor Expression with Downstream Pathway Activation is a Prognostic Predictor of Survival"],"prefix":"10.1245","volume":"14","author":[{"given":"Jason","family":"Foster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"LeVea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaer","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Kuvshinoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miland","family":"Javle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,12,5]]},"reference":[{"key":"9123_CR1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.gastro.2004.09.011","volume":"127","author":"FX Bosch","year":"2004","unstructured":"Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127:5\u201316","journal-title":"Gastroenterology"},{"key":"9123_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.gastro.2004.09.010","volume":"127","author":"LB Seeff","year":"2004","unstructured":"Seeff LB. Introduction: the burden of hepatocellular carcinoma. Gastroenterology 2004; 127:1\u20134","journal-title":"Gastroenterology"},{"key":"9123_CR3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/j.gastro.2004.09.013","volume":"127","author":"HB El-Serag","year":"2004","unstructured":"El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127:27\u201334","journal-title":"Gastroenterology"},{"key":"9123_CR4","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1001\/archsurg.1994.01420310070012","volume":"129","author":"MF Chen","year":"1994","unstructured":"Chen MF, Hwang TL, Jeng LB, et al. Postoperative recurrence of hepatocellular carcinoma. Two hundred five consecutive patients who underwent hepatic resection in 15\u00a0years. Arch Surg 1994; 129:738\u201342","journal-title":"Arch Surg"},{"key":"9123_CR5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1055\/s-2007-1007120","volume":"19","author":"H Bismuth","year":"1999","unstructured":"Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999; 19:311\u201322","journal-title":"Semin Liver Dis"},{"key":"9123_CR6","doi-asserted-by":"crossref","first-page":"18563","DOI":"10.1074\/jbc.M010787200","volume":"276","author":"CH Liu","year":"2001","unstructured":"Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001; 276:18563\u20139","journal-title":"J Biol Chem"},{"key":"9123_CR7","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ijc.10409","volume":"99","author":"J Cheng","year":"2002","unstructured":"Cheng J, Imanishi H, Amuro Y, et al. NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines. Int J Cancer 2002; 99:755\u201361","journal-title":"Int J Cancer"},{"key":"9123_CR8","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1053\/jhep.2002.31774","volume":"35","author":"UC Nzeako","year":"2002","unstructured":"Nzeako UC, Guicciardi ME, Yoon JH, et al. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology 2002; 35:552\u20139","journal-title":"Hepatology"},{"key":"9123_CR9","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.3748\/wjg.v11.i30.4638","volume":"11","author":"M Cervello","year":"2005","unstructured":"Cervello M, Foderaa D, Florena AM, et al. Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis. World J Gastroenterol 2005; 11:4638\u201343","journal-title":"World J Gastroenterol"},{"key":"9123_CR10","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1053\/gast.2001.29691","volume":"121","author":"F Cianchi","year":"2001","unstructured":"Cianchi F, Cortesini C, Bechi P, et al. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001; 121:1339\u201347","journal-title":"Gastroenterology"},{"key":"9123_CR11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1006\/bbrc.2001.4637","volume":"282","author":"MC Jiang","year":"2001","unstructured":"Jiang MC, Liao CF, Lee PH. Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Biochem Biophys Res Commun 2001; 282:671\u20137","journal-title":"Biochem Biophys Res Commun"},{"key":"9123_CR12","first-page":"2555","volume":"60","author":"S Murono","year":"2000","unstructured":"Murono S, Yoshizaki T, Sato H, et al. Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. Cancer Res 2000; 60:2555\u201361","journal-title":"Cancer Res"},{"key":"9123_CR13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0898-6568(01)00192-9","volume":"13","author":"C Liebmann","year":"2001","unstructured":"Liebmann C. Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity. Cell Signal 2001; 13:777\u201385","journal-title":"Cell Signal"},{"key":"9123_CR14","first-page":"553","volume":"19","author":"SV Blank","year":"2005","unstructured":"Blank SV, Chang R, Muggia F. Epidermal growth factor receptor inhibitors for the treatment of epithelial ovarian cancer. Oncology (Huntingt) 2005; 19:553\u20139; discussion 560\u20132, 567","journal-title":"Oncology (Huntingt)"},{"key":"9123_CR15","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.seminoncol.2004.09.015","volume":"31","author":"RG Pomerantz","year":"2004","unstructured":"Pomerantz RG, Grandis JR. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. Semin Oncol 2004; 31:734\u201343","journal-title":"Semin Oncol"},{"key":"9123_CR16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s11864-004-0029-z","volume":"5","author":"KL Tedesco","year":"2004","unstructured":"Tedesco KL, Lockhart AC, Berlin JD. The epidermal growth factor receptor as a target for gastrointestinal cancer therapy. Curr Treat Options Oncol 2004; 5:393\u2013403","journal-title":"Curr Treat Options Oncol"},{"key":"9123_CR17","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/1097-0142(19950315)75:6+<1418::AID-CNCR2820751505>3.0.CO;2-Y","volume":"75","author":"A Tokunaga","year":"1995","unstructured":"Tokunaga A, Onda M, Okuda T, et al. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 1995; 75:1418\u201325","journal-title":"Cancer"},{"key":"9123_CR18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/j.seminoncol.2003.08.006","volume":"30","author":"BP Zhou","year":"2003","unstructured":"Zhou BP, Hung MC. Dysregulation of cellular signaling by HER2\/neu in breast cancer. Semin Oncol 2003; 30:38\u201348","journal-title":"Semin Oncol"},{"key":"9123_CR19","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1158\/0008-5472.CAN-03-3106","volume":"64","author":"JG Jackson","year":"2004","unstructured":"Jackson JG, St Clair P, Sliwkowski MX, et al. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 2004; 64:2601\u20139","journal-title":"Cancer Res"},{"key":"9123_CR20","doi-asserted-by":"crossref","first-page":"28155","DOI":"10.1074\/jbc.273.43.28155","volume":"273","author":"M Hamilton","year":"1998","unstructured":"Hamilton M, Wolfman A. Oncogenic Ha-Ras-dependent mitogen-activated protein kinase activity requires signaling through the epidermal growth factor receptor. J Biol Chem 1998; 273:28155\u201362","journal-title":"J Biol Chem"},{"key":"9123_CR21","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1054\/bjoc.2000.1580","volume":"84","author":"Y Ito","year":"2001","unstructured":"Ito Y, Takeda T, Sakon M, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001; 84:1377\u201383","journal-title":"Br J Cancer"},{"key":"9123_CR22","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/hep.510290355","volume":"29","author":"H Koga","year":"1999","unstructured":"Koga H, Sakisaka S, Ohishi M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999; 29:688\u201396","journal-title":"Hepatology"},{"key":"9123_CR23","first-page":"762","volume":"23","author":"YN Zhao","year":"2004","unstructured":"Zhao YN, Cao J, Wu FX, et al. [Expression and significance of EGF mRNA and EGFR mRNA in hepatocellular carcinoma]. Ai Zheng 2004; 23:762\u20136","journal-title":"Ai Zheng"},{"key":"9123_CR24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-0676.1997.tb00803.x","volume":"17","author":"S Kira","year":"1997","unstructured":"Kira S, Nakanishi T, Suemori S, et al. Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. Liver 1997; 17:177\u201382","journal-title":"Liver"},{"key":"9123_CR25","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3748\/wjg.v8.i5.815","volume":"8","author":"DK Qiu","year":"2002","unstructured":"Qiu DK, Ma X, Peng YS, et al. Significance of cyclooxygenase-2 expression in human primary hepatocellular carcinoma. World J Gastroenterol 2002; 8:815\u20137","journal-title":"World J Gastroenterol"},{"key":"9123_CR26","first-page":"2478","volume":"9","author":"SN Malik","year":"2003","unstructured":"Malik SN, Siu LL, Rowinsky EK, et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 2003; 9:2478\u201386","journal-title":"Clin Cancer Res"},{"key":"9123_CR27","first-page":"135","volume":"85","author":"SN Malik","year":"2003","unstructured":"Malik SN, Bedolla RG, Hidalgo M, et al. Immunohistochemical determination of EGFR-tyrosine kinase inhibition in clinical samples. Methods Mol Med 2003; 85:135\u201340","journal-title":"Methods Mol Med"},{"key":"9123_CR28","first-page":"1168","volume":"8","author":"SN Malik","year":"2002","unstructured":"Malik SN, Brattain M, Ghosh PM, et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002; 8:1168\u201371","journal-title":"Clin Cancer Res"},{"key":"9123_CR29","doi-asserted-by":"crossref","first-page":"31471","DOI":"10.1074\/jbc.273.47.31471","volume":"273","author":"D Jiang","year":"1998","unstructured":"Jiang D, Yang H, Willson JK, et al. Autocrine transforming growth factor alpha provides a growth advantage to malignant cells by facilitating re-entry into the cell cycle from suboptimal growth states. J Biol Chem 1998; 273:31471\u20139","journal-title":"J Biol Chem"},{"key":"9123_CR30","first-page":"1653","volume":"51","author":"MM Javle","year":"2004","unstructured":"Javle MM, Tan D, Yu J, et al. Nuclear surviving expression predicts poor outcome in cholangiocarcinoma. Hepatogastroenterology 2004; 51:1653\u20137","journal-title":"Hepatogastroenterology"},{"key":"9123_CR31","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.1073\/pnas.121016998","volume":"98","author":"S Murono","year":"2001","unstructured":"Murono S, Inoue H, Tanabe T, et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA 2001; 98:6905\u201310","journal-title":"Proc Natl Acad Sci USA"},{"key":"9123_CR32","first-page":"407","volume":"46","author":"G Shiota","year":"1999","unstructured":"Shiota G, Okubo M, Noumi T, et al. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999; 46:407\u201312","journal-title":"Hepatogastroenterology"},{"key":"9123_CR33","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0898-6568(99)00060-1","volume":"11","author":"S Sipeki","year":"1999","unstructured":"Sipeki S, Bander E, Buday L, et al. Phosphatidylinositol 3-kinase contributes to Erk1\/Erk2 MAP kinase activation associated with hepatocyte growth factor-induced cell scattering. Cell Signal 1999; 11:885\u201390","journal-title":"Cell Signal"},{"key":"9123_CR34","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1054\/bjoc.2001.1815","volume":"84","author":"F Liu","year":"2001","unstructured":"Liu F, Qi HL, Chen HL. Regulation of differentiation- and proliferation-inducers on Lewis antigens, alpha-fucosyltransferase and metastatic potential in hepatocarcinoma cells. Br J Cancer 2001; 84:1556\u201363","journal-title":"Br J Cancer"},{"key":"9123_CR35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3748\/wjg.v7.i3.335","volume":"7","author":"Q Wang","year":"2001","unstructured":"Wang Q, Lin ZY, Feng XL. Alterations in metastatic properties of hepatocellular carcinoma cell following H-ras oncogene transfection. World J Gastroenterol 2001; 7:335\u20139","journal-title":"World J Gastroenterol"},{"key":"9123_CR36","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1023\/A:1005824802617","volume":"35","author":"P Tang","year":"1997","unstructured":"Tang P, Steck PA, Yung WK. The autocrine loop of TGF-alpha\/EGFR and brain tumors. J Neurooncol 1997; 35:303\u201314","journal-title":"J Neurooncol"},{"key":"9123_CR37","first-page":"3881","volume":"24","author":"M Hambek","year":"2004","unstructured":"Hambek M, Baghi M, Strebhardt K, et al. STAT 3 activation in head and neck squamous cell carcinomas is controlled by the EGFR. Anticancer Res 2004; 24:3881\u20136","journal-title":"Anticancer Res"},{"key":"9123_CR38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0083-6729(04)67012-9","volume":"67","author":"SB Gibson","year":"2004","unstructured":"Gibson SB. Epidermal growth factor and trail interactions in epithelial-derived cells. Vitam Horm 2004; 67:207\u201327","journal-title":"Vitam Horm"},{"key":"9123_CR39","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1593\/neo.05193","volume":"7","author":"K Yokoi","year":"2005","unstructured":"Yokoi K, Kim SJ, Thaker P, et al. Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice. Neoplasia 2005; 7:696\u2013704","journal-title":"Neoplasia"},{"key":"9123_CR40","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/jnci\/dji238","volume":"97","author":"T Mukohara","year":"2005","unstructured":"Mukohara T, Engelman JA, Hanna NH, et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005; 97:1185\u201394","journal-title":"J Natl Cancer Inst"},{"key":"9123_CR41","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ygyno.2004.01.006","volume":"93","author":"CM Lee","year":"2004","unstructured":"Lee CM, Lee RJ, Hammond E, et al. Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis. Gynecol Oncol 2004; 93:209\u201314","journal-title":"Gynecol Oncol"},{"key":"9123_CR42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijrobp.2004.09.047","volume":"62","author":"A Chakravarti","year":"2005","unstructured":"Chakravarti A, Winter K, Wu CL, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005; 62:309\u201317","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"9123_CR43","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1378\/chest.127.6.2292","volume":"127","author":"O Altundag","year":"2005","unstructured":"Altundag O, Altundag K, Morandi P, et al. Association between epidermal growth factor receptor mutation and improved survival in never-smokers with primary adenocarcinoma of the lung. Chest 2005; 127:2292","journal-title":"Chest"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-006-9123-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-006-9123-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-006-9123-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T16:23:05Z","timestamp":1572970985000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-006-9123-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,5]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["9123"],"URL":"https:\/\/doi.org\/10.1245\/s10434-006-9123-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12,5]]}}}